globenewswire

New York, United States, June 25, 2026 (GLOBE NEWSWIRE) -- The partnership strengthens the network where institutional deal flow converges and follows the onboarding of CBRE, JLL, Cushman & Wakefield, Avison Young and others over the past 18 months

Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the University of Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus^®ONE¹ system.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Futu Holdings Limited (NASDAQ: FUTU) resulting from allegations that Futu may have issued materially misleading business information to the investing public.

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.

TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- (TSX: IMP; OTCQB: ITMSF) – Intermap Technologies Corporation (“Intermap” or the “Company”) held its annual general meeting of shareholders (the “Meeting”) on June 24, 2026, at the TMX Market Centre, Bourse Room, located at 120 Adelaide St W, Toronto, Ontario. A total of 22,993,978 Class A common shares of Intermap (“Common Shares”), representing 31.16% of the total Common Shares outstanding, were represented in person or by proxy at the Meeting.

LONDON, Ontario, 25 juin 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc.. (« Aduro » ou la « Société ») (Nasdaq : ADUR) (TSX : ACT) (FSE : 9D5), une société spécialisée dans les technologies propres qui recycle chimiquement les matières premières de plus faible valeur comme les déchets plastiques, le bitume lourd ou les huiles renouvelables pour les transformer en ressources adaptées au XXI^e siècle, a annoncé aujourd’hui, suite à ses communiqués de presse des 10 juin 2026 et 15 juin 2026, la clôture d’un placement privé sans intermédiaire pour un produit brut de 9 155 940,80 dollars canadiens (6 564 810,21 dollars américains) provenant de la vente de 431 884 actions ordinaires (les « actions LIFE ») au prix de 21,20 dollars canadiens (15,20 dollars américains) par action LIFE (l’« Offre LIFE ») en vertu de la Dispense LIFE (telle que définie aux présentes).

Optimized capital structure, retiring short-term maturing debt

New York, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company focused on developing clean energy solutions, today announced recent and upcoming high-profile engagements with government officials, industry leaders, multilateral organizations, and energy stakeholders across Asia, Africa, Latin America, and the Caribbean as well as a management team update.

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —